Dear Editor, Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly and developed into a global pandemic since its outbreak in December 2019. Currently, there is no antiviral treatment available for human use. Numerous compounds, such as remdesivir and chloroquine, have been reported to inhibit SARS-CoV-2 replication effectively in vitro, but for most of them, the in vivo efficacies against SARS-CoV-2 are still under clinical studies, and for chloroquine, a drug with prominent in vitro antiviral activity, it has been found no beneficial effect for COVID-19 patients in the recent largest study. It is thus urgent to speed up large-scale screening to discover drug candidates to treat COVID-19. Recently, several high throughput screening (HTS) assays had been developed for SARS-CoV-2 antiviral discovery. A virtual screening and a fluorogenic protease enzymatic assay based on the main protease of SARS-CoV-2 have been established to screen the protease inhibitors. A reporter gene system had been developed to screen inhibitors targeting the-1 ribosomal frameshifting of SARS-CoV-2. 1 These systems select the inhibitors targeting to one specific step during infection. Here, we established a cytopathic effect (CPE)-based HTS assay in Vero-E6 cells that are permissive to SARS-CoV-2 infection to screen for inhibitors aiming to the entire viral life cyle. The antiviral efficacy of compounds was determined by the reduction of CPE, which was quantified by measuring cell viability using CCK-8 assay. The HTS conditions, including the cell density, the multiplicity of infection (MOI) and the time of incubation were first optimized in a 96-well format. The final HTS conditions were at 5000 cells/well, 0.01 of MOI, 48 h of incubation to achieve maximum assay sensitivity (producing consistently > 90% CPE in the Vero-E6 cells at endpoint) for drug screening (Supplementary Fig. S1a and Fig. 1a). Multiple known inhibitors, including remdesivir, chloroquine, neutralizing human antibody CB6 2 and IFN-α were used as positive controls to validate the availability of the CPE-based HTS assay. Consistent with previous results, all these reagents provided protection against SARS-CoV-2 infection, and the Z′ values were 0.68, 0.56, 0.66, and 0.58, respectively (HTS assays with Z′ ≥ 0.5 are considered robust) (Supplementary Fig. S1b). These results demonstrated that this CPE-based HTS assay is reliable and robust for screening inhibitors of SARS-CoV-2. As the compound is usually dissolved in DMSO, we also tested the effect of different concentrations of DMSO on SARS-CoV-2 replication to determine the optimal solvent concentration for the assay. As shown in supplementary Fig. S1c, DMSO had no effect on cell viability at ≤1% (v/v) concentration. Therefore, we chose 0.25% DMSO as the working concentration to dissolve the compounds. To further verify the reliability of the selected conditions, we evaluated the inhibitory effects of different concentrations of chloroquine on SARS-CoV-2 infection under the above HTS